41 documents

Read All
11:51 , Apr 18, 2019 |  BC Innovations  |  Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods. Current image analysis tools work well...
Read More
22:45 , Apr 12, 2019 |  BioCentury  |  Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
Read More
18:55 , Oct 27, 2017 |  BC Week In Review  |  Company News

Evotec, MaRS Innovation open LAB150

In September, MaRS Innovation (Toronto, Ontario) and Evotec AG (Xetra:EVT) partnered to open the Toronto-based LAB150 accelerator. The five-year partnership will use Evotec's infrastructure to shorten the drug discovery timeline by designating $75,000-$400,000 to 3-5...
Read More
20:13 , Feb 10, 2017 |  BC Week In Review  |  Financial News

Fibrocor completes venture financing

On Jan. 17, fibrotic disease company Fibrocor Therapeutics L.P. (Toronto, Ontario) raised C$2.8 million ($2.1 million) in a venture round with Evotec AG and MaRS Innovation . Fibrocor said the amount includes "cash, management and...
Read More
18:38 , Nov 18, 2016 |  BioCentury  |  Emerging Company Profile

Suppressing somatostatin

Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy. In Type I diabetes, somatostatin production is elevated, leading to continuous...
Read More
07:00 , Oct 20, 2016 |  BC Innovations  |  Finance

3Q16 Public-Private Partnership Roundup

  Formation of new PPPs cooled off considerably this summer after a blistering pace in 2Q16, with the fewest preclinical research-oriented partnerships since 3Q14. Only 37 partnerships were recorded by BioCentury in 3Q16, a nearly...
Read More
08:00 , Feb 22, 2016 |  BC Week In Review  |  Financial News

ScarX completes venture financing

ScarX Therapeutics Inc. , Toronto, Ontario   Business: Dermatology   Date completed: 2016-02-16   Type: Venture financing   Raised: C$2 million ($1.4 million)   Investors: Accel-Rx Health Sciences Accelerator; BDC Capital; MaRS Innovation ; and...
Read More
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Encycle Therapeutics completes venture financing

Encycle Therapeutics Inc. , Toronto, Ontario   Business: Chemistry, Autoimmune, Cancer   Date completed: 2015-09-30   Type: Venture financing   Raised: C$2.9 million ($2.1 million)   Investors: Takeda Ventures Inc.; Accel-Rx Health Sciences Accelerator; BDC...
Read More
01:12 , Sep 9, 2015 |  BC Extra  |  Company News

J&J to launch JLABS incubator in Toronto

Johnson & Johnson (NYSE:JNJ) plans to launch a JLABS incubator in Toronto, Ontario. Dubbed JLABS @ Toronto, the incubator can house up to 50 life science start-ups, and is expected to open in spring 2016....
Read More
07:00 , Aug 24, 2015 |  BioCentury  |  Finance

Versant bites at the apple

Versant Ventures was to announce on Monday this week that it has selected New York City as the newest leg of its geographic strategy. The firm expects the region will fit the mold of its...
Read More